YMAB - Y-mAbs Therapeutics Inc Stock Price, Fair Value and News

11.60USD-0.25 (-2.11%)Delayed

Market Summary

USD11.60-0.25

Delayed

-2.11%

YMAB Alerts

Losses in recent quarter

YMAB Stock Price

View Fullscreen

YMAB RSI Chart

YMAB Valuation

Market Cap

509.0M

Price/Earnings (Trailing)

-23.49

Price/Sales (Trailing)

6.02

EV/EBITDA

-21.41

Price/Free Cashflow

-28.95

YMAB Price/Sales (Trailing)

YMAB Profitability

EBT Margin

-24.79%

Return on Equity

-21.84%

Return on Assets

-17.57%

Free Cashflow Yield

-3.45%

YMAB Fundamentals

YMAB Revenue

Revenue (TTM)

84.5M

Rev. Growth (Yr)

-1.58%

Rev. Growth (Qtr)

-14.69%

YMAB Earnings

Earnings (TTM)

-21.7M

Earnings Growth (Yr)

-3.74%

Earnings Growth (Qtr)

-570.95%

Breaking Down YMAB Revenue

Last 7 days

-5.5%

Last 30 days

-23.2%

Last 90 days

-28.8%

Trailing 12 Months

12.2%

How does YMAB drawdown profile look like?

YMAB Financial Health

Current Ratio

6.15

YMAB Investor Care

Shares Dilution (1Y)

0.47%

Diluted EPS (TTM)

-0.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	84.5M	0	0	0
2023	75.0M	85.0M	92.9M	84.8M
2022	40.0M	39.8M	43.4M	65.3M
2021	29.2M	37.6M	46.0M	34.9M
2020	0	0	0	20.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Y-mAbs Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 12, 2024	tagliaferri mary	acquired	-	-	4,660	-
Mar 05, 2024	gad thomas	sold	-64,116	16.44	-3,900	chief business officer
Mar 05, 2024	smith susan laura	sold	-27,837	16.55	-1,682	svp & chief commercial officer
Mar 05, 2024	rajah vignesh	sold	-28,282	16.53	-1,711	svp & chief medical officer
Feb 12, 2024	rossi michael j	acquired	-	-	35,700	president & ceo
Jan 18, 2024	wilms joris	acquired	-	-	17,800	svp & chief operating officer
Jan 18, 2024	kruse bo	acquired	-	-	18,100	evp, cfo, secry & treas.
Jan 18, 2024	lisby steen	acquired	-	-	17,800	svp & chief scientific officer
Jan 18, 2024	smith susan laura	acquired	-	-	17,800	svp & chief commercial officer
Jan 18, 2024	gad thomas	acquired	-	-	22,100	chief business officer

Which funds bought or sold YMAB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	211	1,414,220	1,634,420	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.9	18,860	60,162	-%
May 15, 2024	Point72 Asset Management, L.P.	new	-	24,830,600	24,830,600	0.06%
May 15, 2024	Aquatic Capital Management LLC	new	-	53,658	53,658	-%
May 15, 2024	STATE STREET CORP	reduced	-1.37	7,018,800	12,212,400	-%
May 15, 2024	WELLINGTON MANAGEMENT GROUP LLP	new	-	2,378,890	2,378,890	-%
May 15, 2024	JACOBS LEVY EQUITY MANAGEMENT, INC	reduced	-39.1	779,386	2,504,300	0.01%
May 15, 2024	DEUTSCHE BANK AG\	reduced	-0.13	175,782	303,071	-%
May 15, 2024	MORGAN STANLEY	reduced	-23.27	1,386,570	3,058,460	-%
May 15, 2024	AQR CAPITAL MANAGEMENT LLC	new	-	615,294	615,294	-%

Are Funds Buying or Selling YMAB?

Are funds buying YMAB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own YMAB

No. of Funds

YMAB Alerts

Losses in recent quarter

Unveiling Y-mAbs Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 08, 2024	paradigm biocapital advisors lp	5.02%	2,198,312	SC 13G
Feb 14, 2024	wg biotech aps	10.4%	4,559,233	SC 13G/A
Feb 13, 2024	hbm healthcare investments (cayman) ltd.	7.6%	3,297,800	SC 13G/A
Feb 13, 2024	vanguard group inc	5.14%	2,244,238	SC 13G/A
Feb 06, 2024	acorn bioventures, l.p.	2.7%	1,159,966	SC 13G/A
Jan 26, 2024	blackrock inc.	6.7%	2,917,080	SC 13G/A
Apr 03, 2023	acorn bioventures, l.p.	2.2%	977,142	SC 13G
Feb 14, 2023	wg biotech aps	9.6%	4,178,465	SC 13G
Feb 14, 2023	hbm healthcare investments (cayman) ltd.	8.7%	3,813,853	SC 13G/A
Feb 09, 2023	vanguard group inc	5.17%	2,258,254	SC 13G

Recent SEC filings of Y-mAbs Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 29, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 08, 2024	SC 13G	Major Ownership Report
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	8-K	Current Report
Mar 08, 2024	3	Insider Trading

Peers (Alternatives to Y-mAbs Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.57	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Y-mAbs Therapeutics Inc News

Latest updates

Y-mAbs Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	-14.7%	19,931,000	23,363,000	20,454,000	20,751,000	20,251,000	31,447,000	12,537,000	10,797,000	10,486,000	9,598,000	8,965,000	10,951,000	5,383,000	20,750,000
Costs and Expenses	1.0%	26,839,000	26,562,000	28,203,000	27,974,000	27,752,000	32,600,500	38,554,000	50,742,000	38,181,000	45,356,000	37,669,000	33,663,000	33,642,000	40,844,500
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	40,844,500
S&GA Expenses	2.6%	11,425,000	11,135,000	10,200,000	11,270,000	12,251,000	10,793,000	13,626,000	23,082,000	13,438,000	15,138,000	13,988,000	13,475,000	11,970,000	14,630,500
R&D Expenses	-0.9%	13,267,000	13,388,000	15,358,000	12,055,000	13,418,000	19,787,000	22,453,000	26,420,000	22,912,000	28,757,000	23,131,000	19,778,000	21,579,000	24,011,000
EBITDA Margin	-0.9%	-0.24	-0.24	-1.02	-1.11	-1.26	-1.45	-	-	-	-	-	-	-	-
Income Taxes	-17.9%	160,000	195,000	187,000	179,000	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-715.8%	-6,469,000	-793,000	-7,560,000	-6,123,000	-6,390,000	-	-27,526,000	-41,131,000	-	-	-	-	-	-
EBT Margin	-0.8%	-0.25	-0.25	-1.03	-1.12	-1.27	-1.46	-	-	-	-	-	-	-	-
Net Income	-571.0%	-6,629,000	-988,000	-7,747,000	-6,302,000	-6,390,000	1,157,000	-27,526,000	-41,131,000	-28,068,000	-36,893,000	-28,858,000	-22,937,000	33,413,000	-19,933,000
Net Income Margin	-1.5%	-0.26	-0.25	-0.21	-0.46	-0.98	-1.46	-3.08	-3.39	-2.92	-1.58	-0.83	-1.12	-2.05	-
Free Cashflow	56.7%	-3,477,000	-8,036,000	-1,493,000	-4,889,000	-13,279,000	-8,816,000	-19,390,000	-23,255,000	-25,080,000	-34,018,000	-18,147,000	-18,797,000	-32,261,000	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-3.6%	123	128	129	132	137	141	144	165	191	213	240	259	275	132	143	167	194	216	104	126	140
Current Assets	-2.6%	108	111	115	116	124	130	133	154	178	202	231	249	264	122	133	163	190	212	100	123	137
Cash Equivalents	-3.7%	76.00	79.00	87.00	88.00	93.00	106	115	134	157	182	216	234	252	115	131	158	186	207	98.00	120	134
Inventory	66.8%	8.00	5.00	7.00	5.00	9.00	7.00	6.00	7.00	6.00	6.00	5.00	4.00	1.00	-	-	-	-	-	-	-	-
Net PPE	-31.7%	0.00	0.00	0.00	0.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	0.00	0.00
Liabilities	-10.3%	24.00	27.00	29.00	28.00	30.00	32.00	36.00	34.00	34.00	33.00	29.00	25.00	23.00	26.00	27.00	21.00	19.00	17.00	18.00	18.00	14.00
Current Liabilities	-12.5%	18.00	20.00	22.00	24.00	26.00	28.00	32.00	29.00	29.00	28.00	25.00	21.00	17.00	20.00	20.00	16.00	15.00	14.00	14.00	14.00	10.00
Shareholder's Equity	-1.8%	99.00	101	100	105	108	109	108	131	157	180	211	234	252	106	117	146	175	199	86.00	108	126
Retained Earnings	-1.4%	-464	-457	-456	-448	-442	-436	-437	-409	-368	-340	-303	-274	-251	-285	-265	-232	-192	-165	-142	-118	-100
Additional Paid-In Capital	0.8%	562	558	555	552	549	544	540	538	524	519	514	509	504	392	382	378	367	365	229	227	226
Shares Outstanding	0.4%	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	43.00	42.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	246	-	-	-	551	-	-	-	1,000	-	-	-	990	-	-	-	296	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	56.7%	-3,477	-8,036	-1,338	-4,734	-13,124	-8,661	-19,235	-23,100	-24,925	-33,863	-18,076	-18,756	-31,861	-17,695	-24,145	-27,635	-21,756	-24,579	-21,395	-14,040	-13,483
Share Based Compensation	23.2%	3,846	3,123	2,410	3,616	5,304	3,537	3,341	13,633	5,091	4,908	4,901	4,827	4,698	8,336	3,134	2,454	2,211	1,477	1,345	971	864
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-455	-71.00	-41.00	61,610	-44.00	-2,713	-2.00	-26.00	-1,147	-617	-75.00	-126
Cashflow From Financing	-	588	-	-	-	-	-	52.00	-	32.00	100	248	131	107,835	1,419	215	-	370	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

YMAB Income Statement

2024-03-31

Consolidated Statements of Net Loss and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
REVENUES
Total revenues	$ 19,931	$ 20,251
OPERATING COSTS AND EXPENSES
Cost of goods sold	2,097	2,083
License royalties	50
Research and development	13,267	13,418
Selling, general, and administrative	11,425	12,251
Total operating costs and expenses	26,839	27,752
Loss from operations	(6,908)	(7,501)
OTHER INCOME, NET
Interest and other income	439	1,111
LOSS BEFORE INCOME TAXES	(6,469)	(6,390)
Provision for income taxes	160
NET LOSS	(6,629)	(6,390)
Other comprehensive income/(loss)
Foreign currency translation	399	(306)
COMPREHENSIVE LOSS	$ (6,230)	$ (6,696)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.15)	$ (0.15)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.15)	$ (0.15)
Weighted average common shares outstanding, basic (in shares)	43,779,456	43,671,589
Weighted average common shares outstanding, diluted (in shares)	43,779,456	43,671,589
Product
REVENUES
Total revenues	$ 19,431	$ 20,251
License
REVENUES
Total revenues	$ 500

YMAB Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS
Cash and cash equivalents	$ 75,749	$ 78,637
Accounts receivable, net	20,588	22,454
Inventories	8,448	5,065
Other current assets	3,482	4,955
Total current assets	108,267	111,111
Property and equipment, net	153	224
Operating lease right-of-use assets	1,179	1,412
Intangible assets, net	2,543	2,631
Other assets	11,173	12,491
TOTAL ASSETS	123,315	127,869
LIABILITIES
Accounts payable	6,728	6,060
Accrued liabilities	9,989	13,166
Operating lease liabilities, current portion	888	902
Total current liabilities	17,605	20,128
Accrued milestone and royalty payments	5,375	5,375
Operating lease liabilities, long-term portion	293	517
Other liabilities	853	864
TOTAL LIABILITIES	24,126	26,884
Commitments and contingencies (Note 9)
STOCKHOLDERS' EQUITY
Preferred stock, $0.0001 par value, 5,500,000 shares authorized and none issued at March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value, 100,000,000 shares authorized at March 31, 2024 and December 31, 2023; 43,852,638 and 43,672,112 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	4	4
Additional paid-in capital	562,436	558,002
Accumulated other comprehensive income	848	449
Accumulated deficit	(464,099)	(457,470)
TOTAL STOCKHOLDERS' EQUITY	99,189	100,985
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 123,315	$ 127,869

About Y-mAbs Therapeutics Inc

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody which has completed pivotal phase 2 clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, and Omburtamab 03-133 that is in phase 1 clinical trials for the treatment of intrathecal immunotherapy for CNS/leptomeningeal metastases. In addition, its product pipeline includes huB7-H3 for the treatment of systemic solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

CEO	Mr. Thomas Gad
WEBSITE	ymabs.com
INDUSTRY	Biotechnology
EMPLOYEES	147

Y-mAbs Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Y-mAbs Therapeutics Inc? What does YMAB stand for in stocks?

YMAB is the stock ticker symbol of Y-mAbs Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Y-mAbs Therapeutics Inc (YMAB)?

As of Fri May 17 2024, market cap of Y-mAbs Therapeutics Inc is 509.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of YMAB stock?

You can check YMAB's fair value in chart for subscribers.

What is the fair value of YMAB stock?

You can check YMAB's fair value in chart for subscribers. The fair value of Y-mAbs Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Y-mAbs Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for YMAB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Y-mAbs Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether YMAB is over valued or under valued. Whether Y-mAbs Therapeutics Inc is cheap or expensive depends on the assumptions which impact Y-mAbs Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for YMAB.

What is Y-mAbs Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, YMAB's PE ratio (Price to Earnings) is -23.49 and Price to Sales (PS) ratio is 6.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. YMAB PE ratio will change depending on the future growth rate expectations of investors.